2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events A 2024 Meta-analysis of 13 multiple cardiovascular outcome trials has documented that GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
Pamela Berens, M.D., a professor and OB-GYN with UTHealth Houston Faith Ohuoba, M.D., an OB-GYN at Memorial Hermann Health System in Houston, Texas, and a clinical associate professor at the University of Houston Jamie Stanhiser, M.D., M.S.C.R., a reproductive endocrinologist and fertility specialist at Reproductive Partners Fertility Center in San Diego Our skilled fertility specialists are here to help
Cost: How does Pendulum compare in terms of affordability with its closest competitors
Cloudiness often indicates bacterial contamination or that the peptide has begun to aggregate and fall out of solution
Rather than protecting the peptide through the stomach, this formulation aims for sublingual and buccal absorption
